API Pharma

API Pharma As seen on Fox News Dana Perino Daily Briefing. Join us in putting America back to work!

Covid-Rapid (Covid Rapid) COVID-19 test-kits are manufactured by API, with over a decade of experience fighting infectious diseases.

Recent studies found that T cells found in COVID-19 patients ‘bode well’ for long-term immunity.T cells are a type of wh...
05/19/2020

Recent studies found that T cells found in COVID-19 patients ‘bode well’ for long-term immunity.

T cells are a type of white blood cell that the immune system uses to help fight viruses.

Scientists found that in people who had recovered from COVID-19, the T cells react to SARS-CoV-2 virus, the cause of the disease.

This study reveals new information that will help researchers better understand immunity.

Read the full story: https://www.sciencemag.org/news/2020/05/t-cells-found-covid-19-patients-bode-well-long-term-immunity?fbclid=IwAR2JomL5K_XZ2K8eq9Z1FjIWZG2AsIWlINmq5o8nm6iaPpYDYMqfMvnErNc #

New findings suggest past infections may offer some protection against the novel coronavirus

Hear from our founder Dr. Vincent DeGennaro on the Pensacola Morning News on NewsRadio1620.Dr. DeGennaro and Andrew McKa...
05/11/2020

Hear from our founder Dr. Vincent DeGennaro on the Pensacola Morning News on NewsRadio1620.

Dr. DeGennaro and Andrew McKay discuss the way API's Covid-rapid works and how it solves for some of the concerns about accuracy for antibody tests that look for the novel coronavirus.

Listen to the interview below and learn more on our website https://covid-rapid.com

Andrew McKay and Dr. DeGennero (Epidemiologist and Medical Director/CEO of Abacus Pharma International) discuss the new rapid COVID-19 antibody test from Sure Bio-Tech and distributed by API which fun

In a breakthrough study about   immunity, South Korean scientists found that people cannot be infected twice with the vi...
05/06/2020

In a breakthrough study about immunity, South Korean scientists found that people cannot be infected twice with the virus. This result means that once a person has had Covid-19 (even if they are asymptomatic), they will be immune in the future.

Tests like Covid-Rapid are critical in understanding who has the antibodies that indicate this immunity. Once a person has been exposed to the virus, antibodies develop, and Covid-Rapid detects the presence of these antibodies in just ten minutes.

Read the whole story: https://news.sky.com/story/amp/coronavirus-scientists-conclude-people-cannot-be-infected-twice-11981721

Learn more about Covid-Rapid on our website: https://www.covid-rapid.com

A total of 277 patients in the country were believed to have fallen ill for a second time, as had patients in China and Japan.

Address

1521 Alton Road #369
South Beach, FL
33139

Alerts

Be the first to know and let us send you an email when API Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

With a decade of experience in other infectious diseases, API quickly applied its expertise to fight COVID-19. In less than two weeks, hundreds of thousands of Covid-Rapid tests can be available in the United States.

API manufactures over 200 types of rapid diagnostic tests internationally, all of which can be done in an outpatient setting without a lab or specially trained staff. All its rapid tests cost between $8 and $29, offering patients, doctors, clinicians and the healthcare community significant value for their money.

API was founded by Joseph Trentin to contract manufacture low-cost USP or BP standard generic pharmaceuticals. In addition, API manufactures all-natural vegetarian, non-GMO, gluten free, nutrients for the USA and Latin America commercial markets. Abacus Pharma International, based in Alexandria, Virginia, helps design rapid tests outside the USA for a range of viruses and diseases, such as herpes, HIV, Hepatitis, sexually transmitted diseases, rotovirus and the flu, among others. API's founder has worked for more than 20 years in the pharmaceutical business, including for GlaxoSmithKline. API’s medical director is Dr. Vincent DeGennaro, an internist and public health specialist who has worked in ten countries around the world implementing public health programs focused on disaster relief and chronic disease management. A portion of all our sales go to promote the health and well-being of those in low-income countries, including free test kits.